Prime Medicine Achieves First In Vivo Prime Editing for Wilson Disease
Prime Medicine has treated the first patient using prime editing directly inside the body to address Wilson disease, a rare genetic condition. This marks the first known instance of in vivo prime editing, offering a potential one-time cure by correcting faulty DNA in liver cells to manage copper buildup. The trial aims to replace current complex medication regimens with a permanent genetic fix, with initial results expected next year.
Key points
- Prime Medicine, based in Cambridge, Massachusetts, announced the treatment of its first patient using prime editing in vivo earlier this month.
- The technique targets Wilson disease by rewriting DNA in liver cells to correct mutations in the ATP7B gene, which normally helps eliminate excess copper.
- Unlike standard CRISPR-Cas9, which often disables genes, or base editing, which cannot fix specific ATP7B mutations, prime editing can insert, delete, and rewrite DNA segments with high precision.
- The company expects to release the first results from this clinical trial next year, potentially offering a lasting solution for patients currently reliant on copper-clearing medications.
- This in vivo approach differs from ex vivo methods, where cells are edited in a lab and reinserted, by directly altering DNA within the body, potentially lowering costs and speeding up treatment delivery.
Background
Recent advancements in gene editing have expanded beyond traditional CRISPR-Cas9 limitations. In September 2026, researchers developed 'prime assembly' for large-scale precise editing in non-dividing cells, and earlier in October, teams mapped mouse embryo development using prime editing technologies. These developments highlight a broader trend toward more versatile and precise genome engineering tools. Additionally, the FDA is expected to decide soon on an in vivo CRISPR-Cas9 therapy for hereditary angioedema, indicating growing regulatory interest in direct in-body gene editing approaches.
Why it matters
This milestone represents a significant shift in genetic therapy from ex vivo to in vivo applications, potentially making treatments more accessible and affordable. For patients with rare diseases like Wilson disease, a one-time genetic correction could replace lifelong, complex medication regimens. The success of prime editing in vivo could pave the way for broader applications in treating other genetic disorders that require precise DNA corrections rather than simple gene silencing.
What to watch
Prime Medicine plans to announce the first results from its Wilson disease trial next year. The FDA is also expected to issue a decision early next year regarding an in vivo CRISPR-Cas9 therapy for hereditary angioedema. Continued monitoring of safety and efficacy will be crucial as these in vivo approaches move from experimental trials to potential standard treatments.
Want the full story? Read the original reporting
Read on Nature